CBD combined with ginseng compound in nanoparticles achieved 82% tumor inhibition in breast cancer mice
CBD co-loaded with a ginseng compound (PPD) into liposomal nanoparticles showed dose-dependent anti-tumor effects in breast cancer mice, achieving 82.2% tumor inhibition with good tolerability.
Quick Facts
What This Study Found
CBD and 20(S)-Protopanaxadiol (PPD, from ginseng) co-loaded into liposomes (mean particle size 138.8 nm) achieved 82.2% tumor inhibition in mice bearing breast tumors (4T1 cells) with good tolerance. However, adding glucose-targeting modifications did not significantly improve the results.
Key Numbers
Liposome size: 138.8 nm. Tumor inhibition rate: 82.2% with good dose dependence. In vivo mouse model using 4T1 breast cancer cells.
How They Did This
Liposomal nanoparticle formulation study with in vivo testing in BALB/c mice bearing 4T1 breast tumors. Compared CBD-PPD liposomes to glycosyl-modified versions targeting GLUT1 receptors on tumor cells.
Why This Research Matters
CBD has shown anti-tumor potential but faces delivery challenges. Combining it with PPD in nanoparticles may enhance efficacy while maintaining tolerability, and CBD may also address cancer-associated pain, anxiety, and cachexia.
The Bigger Picture
CBD's unique profile of anti-tumor effects plus symptom management (pain, anxiety, cachexia) makes it a particularly interesting candidate for cancer treatment, especially when delivery challenges are overcome.
What This Study Doesn't Tell Us
Mouse model only. Single tumor type (4T1). Glucose-targeting modification did not improve results. Human pharmacokinetics and tumor penetration would differ from mice.
Questions This Raises
- ?Would CBD-PPD liposomes work against other cancer types?
- ?Can nanoparticle delivery achieve therapeutic CBD concentrations in human tumors?
Trust & Context
- Key Stat:
- 82.2% tumor inhibition rate with good tolerance
- Evidence Grade:
- Animal study with a single tumor model. Promising formulation approach but far from clinical application.
- Study Age:
- Published in 2022.
- Original Title:
- Improved Therapeutic Efficacy of CBD with Good Tolerance in the Treatment of Breast Cancer through Nanoencapsulation and in Combination with 20(S)-Protopanaxadiol (PPD).
- Published In:
- Pharmaceutics, 14(8) (2022)
- Authors:
- Fu, Jingxin, Zhang, Kunfeng, Lu, Likang, Li, Manzhen, Han, Meihua, Guo, Yifei, Wang, Xiangtao
- Database ID:
- RTHC-03852
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why combine CBD with a ginseng compound?
PPD (from ginseng) was added to create a synergistic anti-tumor effect with CBD. The combination in liposomal nanoparticles achieved higher tumor inhibition than what either compound typically achieves alone.
Could this be used to treat breast cancer?
Not yet. This was an animal study showing proof of concept. Human clinical trials would need to confirm safety, efficacy, and optimal dosing before clinical use.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03852APA
Fu, Jingxin; Zhang, Kunfeng; Lu, Likang; Li, Manzhen; Han, Meihua; Guo, Yifei; Wang, Xiangtao. (2022). Improved Therapeutic Efficacy of CBD with Good Tolerance in the Treatment of Breast Cancer through Nanoencapsulation and in Combination with 20(S)-Protopanaxadiol (PPD).. Pharmaceutics, 14(8). https://doi.org/10.3390/pharmaceutics14081533
MLA
Fu, Jingxin, et al. "Improved Therapeutic Efficacy of CBD with Good Tolerance in the Treatment of Breast Cancer through Nanoencapsulation and in Combination with 20(S)-Protopanaxadiol (PPD).." Pharmaceutics, 2022. https://doi.org/10.3390/pharmaceutics14081533
RethinkTHC
RethinkTHC Research Database. "Improved Therapeutic Efficacy of CBD with Good Tolerance in ..." RTHC-03852. Retrieved from https://rethinkthc.com/research/fu-2022-improved-therapeutic-efficacy-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.